Phase 3 CheckMate 067 trial of nivolumab in previously untreated advanced melanoma - European Medical Journal

Phase 3 CheckMate 067 trial of nivolumab in previously untreated advanced melanoma

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The Royal Marsden, London, UK, discusses the phase 3 CheckMate 067 trial. The results of this trial demonstrate a superior progression-free survival of nivolumab (a PD-1 checkpoint inhibitor) and ipilimumab (a CTLA-4 checkpoint inhibitor) regimen or nivolumab monotherapy versus ipilimumab monotherapy in previously untreated advanced melanoma.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>